These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36213666)

  • 21. A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England.
    Buyukkaramikli NC; Wigfield P; Hoang MT
    Eur J Health Econ; 2021 Feb; 22(1):51-73. PubMed ID: 32901420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern European countries.
    Rotar AM; Preda A; Löblová O; Benkovic V; Zawodnik S; Gulacsi L; Niewada M; Boncz I; Petrova G; Dimitrova M; Klazinga N
    Health Policy; 2018 Mar; 122(3):230-236. PubMed ID: 29373186
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Market Access Agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts.
    Jarosławski S; Toumi M
    BMC Health Serv Res; 2011 Oct; 11():259. PubMed ID: 21982545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of transferability guidance for integrated care models with special focus on Central and Eastern European countries.
    Kaló Z; Zemplényi A; Rutten-van Mölken M; Looman W; Huić M; Tandara Haček R; Petrova G; Piniazhko O; Tesar T; Csanádi M; Pitter JG
    Croat Med J; 2020 Jul; 61(3):252-259. PubMed ID: 32643342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Linking Reimbursement to Patient Benefits for Advanced Therapy Medicinal Products and Other High-Cost Innovations: Policy Recommendations for Outcomes-Based Agreements in Europe.
    Avşar TS; Elvidge J; Hawksworth C; Kenny J; Németh B; Callenbach M; Ringkvist J; Dawoud D
    Value Health; 2024 Jul; ():. PubMed ID: 39094693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmaceutical policies: effects of financial incentives for prescribers.
    Rashidian A; Omidvari AH; Vali Y; Sturm H; Oxman AD
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD006731. PubMed ID: 26239041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recommendations to overcome barriers to the use of artificial intelligence-driven evidence in health technology assessment.
    Zemplényi A; Tachkov K; Balkanyi L; Németh B; Petykó ZI; Petrova G; Czech M; Dawoud D; Goettsch W; Gutierrez Ibarluzea I; Hren R; Knies S; Lorenzovici L; Maravic Z; Piniazhko O; Savova A; Manova M; Tesar T; Zerovnik S; Kaló Z
    Front Public Health; 2023; 11():1088121. PubMed ID: 37181704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries.
    Morel T; Arickx F; Befrits G; Siviero P; van der Meijden C; Xoxi E; Simoens S
    Orphanet J Rare Dis; 2013 Dec; 8():198. PubMed ID: 24365263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies.
    Michelsen S; Nachi S; Van Dyck W; Simoens S; Huys I
    Front Pharmacol; 2020; 11():594446. PubMed ID: 33363468
    [No Abstract]   [Full Text] [Related]  

  • 31. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers.
    Carlson JJ; Sullivan SD; Garrison LP; Neumann PJ; Veenstra DL
    Health Policy; 2010 Aug; 96(3):179-90. PubMed ID: 20226559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pricing and Market Access Challenges in the Era of One-Time Administration Cell and Gene Therapies.
    Sabatini MT; Xia T; Chalmers M
    Pharmaceut Med; 2022 Oct; 36(5):265-274. PubMed ID: 35994198
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Guidance on using real-world evidence from Western Europe in Central and Eastern European health policy decision making.
    Németh B; Kamusheva M; Mitkova Z; Petykó ZI; Zemplényi A; Dimitrova M; Tachkov K; Balkányi L; Czech M; Dawoud D; Goettsch W; Hren R; Knies S; Lorenzovici L; Maravic Z; Piniazhko O; Zerovnik S; Kaló Z
    J Comp Eff Res; 2023 Apr; 12(4):e220157. PubMed ID: 36861458
    [No Abstract]   [Full Text] [Related]  

  • 34. Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience.
    Dunlop WCN; Staufer A; Levy P; Edwards GJ
    Health Policy; 2018 May; 122(5):528-532. PubMed ID: 29567205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pricing and Reimbursement of Patent-Protected Medicines: Challenges and Lessons from South-Eastern Europe.
    Vončina L; Strbad T; Fürst J; Dimitrova M; Kamusheva M; Vila M; Mardare I; Hristova K; Harsanyi A; Atanasijević D; Banović I; Bobinac A
    Appl Health Econ Health Policy; 2021 Nov; 19(6):915-927. PubMed ID: 34553334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interface policies bridging outpatient and hospital sectors in Europe: can cross-sectorial collaboration in reimbursement and procurement improve access to affordable medicines?
    Vogler S; Salcher-Konrad M; Habimana K
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(8):867-878. PubMed ID: 37450611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. When Reality Does Not Meet Expectations-Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs.
    Callenbach MHE; Vreman RA; Mantel-Teeuwisse AK; Goettsch WG
    Int J Environ Res Public Health; 2022 Dec; 20(1):. PubMed ID: 36612665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Proposal for Value-Based Managed Entry Agreements in an Environment of Technological Change and Economic Challenge for Publicly Funded Healthcare Systems.
    Xoxi E; Rumi F; Kanavos P; Dauben HP; Gutierrez-Ibarluzea I; Wong O; Rasi G; Cicchetti A
    Front Med Technol; 2022; 4():888404. PubMed ID: 35782579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Payer and Pharmaceutical Manufacturer Considerations for Outcomes-Based Agreements in the United States.
    Brown JD; Sheer R; Pasquale M; Sudharshan L; Axelsen K; Subedi P; Wiederkehr D; Brownfield F; Kamal-Bahl S
    Value Health; 2018 Jan; 21(1):33-40. PubMed ID: 29304938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Performance-based risk-sharing agreements in renal care: current experience and future prospects.
    Drummond M; Federici C; Busink E; Apel C; Kendzia D; Brouwer W
    Expert Rev Pharmacoecon Outcomes Res; 2021 Apr; 21(2):197-209. PubMed ID: 33439090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.